<DOC>
	<DOCNO>NCT02921789</DOCNO>
	<brief_summary>The purpose study assess efficacy bleselumab regimen ( basiliximab induction , tacrolimus , steroid bleselumab ) compare Standard Care ( SOC ) regimen ( basiliximab induction , tacrolimus , steroid mycophenolate mofetil [ MMF ] ) prevention recurrence Focal Segmental Glomerulosclerosis ( FSGS ) define nephrotic range proteinuria protein-creatinine ratio ( &gt; 3.0 g/g ) initiation plasmapheresis evident etiology 3 month post-transplant .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Bleselumab Preventing Recurrence Focal Segmental Glomerulosclerosis de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description>The study consist follow period : Screening ( Days -21 -1 ) , Transplant ( Day 0 ) , Post-Transplant ( Day 0/post-skin closure 12 month post-transplant ) . All subject enter Screening Period ( Days -21 -1 prior transplant ) , undergo Transplant ( Day 0 [ zero ] ) , follow 12 month Post-Transplant Period ( Day 0 12 month post-transplant ) .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Subject recipient de novo kidney living decease donor biopsyproven , primary FSGS cause end stage renal disease ( ESRD ) subject native kidney . Subject anticipate receive first oral dose tacrolimus within 48 hour transplant procedure . Subject must willing able comply study requirement include prohibited concomitant medication restriction . Subject agree participate another interventional study treatment . Subject Induction therapy , studyassigned basiliximab , plan part initial immunosuppressive regimen . Subject diagnosis secondary FSGS ( familial , virus associate , medication , etc . ) define genetic cause FSGS . Subject previously receive organ transplant include kidney . Subject receive kidney part multiorgan transplant . Subject receive dual kidney transplant decease donor . Subject receive kidney anticipate cold ischemia time ( CIT ) &gt; 30 hour . Subject receive kidney meet BOTH Extended Criteria Donor ( ECD ) Donation Cardiac Death ( DCD ) criterion . ( A kidney meet either ECD OR DCD criterion may eligible inclusion . ) Subject receive blood group system incompatible donor kidney . Recipient donor know seropositive human immunodeficiency virus ( HIV ) . Subject current calculate panel reactive antibody ( cPRA ) level &gt; 50 % . Subject current malignancy history malignancy ( within past 5 year ) , except nonmetastatic basal squamous cell carcinoma skin treat successfully , renal cell carcinoma treat successfully 2 year prior transplantation . Subject significant liver disease , define past 21 day consistently elevate aspartate aminotransferase ( AST ) ( SGOT ) and/or alanine aminotransferase ( ALT ) ( SGPT ) level great 1.5 time upper value normal range investigational site . Subject know positive test latent tuberculosis ( TB ) previously receive adequate antimicrobial therapy/or would require TB prophylaxis transplant . Subject uncontrolled concomitant infection unstable medical condition could interfere study objective . Subject concurrently participate another drug study receive investigational drug 30 day 5 halflives prior transplant . Subject currently receive receive 8 week prior transplant immunologic biologic compound ( i.e. , tumor necrosis factor ( TNF ) inhibitor , [ e.g. , etanercept , adalimumab ] , intravenous immunoglobulin ( IVIG ) ) . Subject previously receive bleselumab participate clinical study bleselumab . Subject know hypersensitivity tacrolimus , MMF , basiliximab , corticosteroid , component . Subject form substance abuse , psychiatric disorder , condition could invalidate communication Investigator . Subject clinically significant abnormal electrocardiogram ( ECG ) Screening . Subject unlikely comply visit schedule protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Bleselumab</keyword>
	<keyword>ASKP1240</keyword>
	<keyword>Efficacy Safety</keyword>
</DOC>